ClinicalTrials.gg
CompletedNCT00364923PROPELUpdated Dec 19, 2019Results posted

Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

A Phase 2 interventional study of Pralatrexate Injection in Peripheral T-cell Lymphoma, sponsored by Acrotech Biopharma Inc.. Completed at 32 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-19.

Sponsored by Acrotech Biopharma Inc. (part of Aurobindo Pharma) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
115
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing pralatrexate in Lymphoma, T-Cell, Peripheral — none open to participants now, 1 under way, 1 of them phase 3. pralatrexate · Lymphoma, T-Cell, Peripheral.

Enrollment
3rd of 11
115 · median 48
Started
2006
the only one that year
Phase 2
3 of 11
none open now
Registered
1st of 11
by date
Lead sponsor
5 of 11
Acrotech Biopharma Inc.

Among the 11 studies testing pralatrexate in Lymphoma, T-Cell, Peripheral, this one is the 3rd largest by enrollment, is the only one that started in 2006, is one of 3 in phase 2, and was the 1st registered.

Lymphoma, T-Cell, Peripheral

372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.

Browse Lymphoma, T-Cell, Peripheral studies →

Open to participants now

None of the 11 studies testing pralatrexate in Lymphoma, T-Cell, Peripheral is open now. The open studies under Lymphoma, T-Cell, Peripheral, anywhere →

About pralatrexate

pralatrexate: first FDA approval 2009 (FOLOTYN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing pralatrexate in Lymphoma, T-Cell, Peripheral as a file.
02

Study summary

Primary

  • Determine the efficacy of pralatrexate with concurrent vitamin B12 and folic acid supplementation when administered to patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)

Secondary

  • Determine the safety of pralatrexate with concurrent vitamin B12 and folic acid supplementation when administered to patients with relapsed or refractory PTCL
  • Determine the pharmacokinetic (PK) profile of pralatrexate when administered with vitamin B12 and folic acid supplementation
Read the detailed description

This is a Phase 2, single arm, non-randomized, open-label, multi-center study designed to evaluate the safety and effectiveness of pralatrexate when administered with vitamin B12 and folic acid supplementation to patients with relapsed or refractory PTCL.

Pralatrexate will be given over 3-5 minutes intravenously (IV), which means through a vein. If pralatrexate is tolerated well, the patient will receive IV injections of pralatrexate every week for 6 weeks, followed by 1 week without receiving pralatrexate. These 7 week cycles will be repeated depending on response and tolerability.

03

Conditions studied

  • Peripheral T-cell Lymphoma

Keywords

  • Peripheral T-cell Lymphoma
  • T-cell Lymphoma
  • Lymphoma
  • PDX
  • Pralatrexate
  • Vitamin B12
  • Folic acid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologically/ confirmed PTCL, using the Revised European American Lymphoma (REAL) World Health Organization (WHO) disease classification:

    1. T/Natural Killer (T/NK) cell leukemia/lymphoma
    2. Adult T-cell lymphoma/leukemia (human T-cell leukemia virus [HTLV] 1+)
    3. Angioimmunoblastic T cell lymphoma
    4. Blastic Natural Killer (NK) lymphoma (with skin, lymph node, or visceral involvement)
    5. Anaplastic large cell lymphoma, primary systemic type
    6. PTCL - unspecified
    7. T/NK-cell lymphoma - nasal
    8. Enteropathy-type intestinal lymphoma
    9. Hepatosplenic T cell lymphoma
    10. Extranodal peripheral T/NK-cell lymphoma - unspecified
    11. Subcutaneous panniculitis T-cell lymphoma
    12. Transformed mycosis fungoides
  • Documented progression of disease after at least 1 prior treatment. Patients may not have received experimental therapy as their only prior therapy. Patient has at least 1 from initial diagnosis or in the setting to confirm the diagnosis of PTCL. Patient has recovered from the toxic effects of prior therapy. Patients treated with monoclonal antibody therapy may be enrolled regardless of the time frame of the therapy if they have progression of disease.
  • (ECOG) Performance Status ≤ 2.
  • ≥ 18 years of age.
  • Adequate hematological, hepatic, and renal function.
  • Women of must agree to practice a medically acceptable regimen from study treatment initiation until at least 30 days after the last administration of pralatrexate and must have a negative serum pregnancy test within 14 days prior to the first day of study treatment. Patients who are for at least 1 year or are surgically sterilized do not require this test.
  • Men who are not surgically sterile must agree to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 90 days after the last administration of pralatrexate.
  • Patient has given written .

Exclusion criteria

Exclusion Criteria:

  • Patient has:

    1. Precursor T/NK neoplasms, with the exception of blastic NK lymphoma
    2. T cell prolymphocytic leukemia (T-PLL)
    3. T cell large granular lymphocytic leukemia
    4. Mycosis fungoides, other than transformed mycosis fungoides
    5. Sézary syndrome
    6. Primary cutaneous CD30+ disorders: Anaplastic large cell lymphoma and lymphomatoid papulosis
  • Active concurrent (except non melanoma skin cancer or carcinoma in situ of the cervix). If there is a history of prior malignancy, the patient must be disease free for greater than or equal to 5 years.
  • Congestive heart failure Class III/IV according to the 's Heart Failure Guidelines.
  • Uncontrolled hypertension.
  • (HIV)-positive diagnosis and is receiving combination anti-retroviral therapy.
  • Patient has, or history of, or central nervous system (CNS) disease.
  • Patient has undergone an stem cell transplant.
  • Patient has less than 75 days from time of an autologous stem cell transplant.
  • Active uncontrolled infection, underlying medical condition including unstable cardiac disease, or other serious illness that would impair the ability of the patient to receive protocol treatment.
  • Major surgery within 2 weeks of study entry.
  • Receipt of any conventional chemotherapy or radiation therapy (RT) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study treatment or planned use during the course of the study.
  • Receipt of within 7 days of study treatment, unless patient has been taking a continuous dose of no more than 10 mg/day of prednisone for at least 1 month.
  • Use of any drugs, biologics, or devices within 4 weeks prior to study treatment or planned use during the course of the study.
  • Previous exposure to pralatrexate.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
115 participants (actual)

Interventions

  • Pralatrexate 30 mg/m2 via IV push over 3-5 minutes for 6 weeks in a 7 week cycle.

    Also known as: FOLOTYN, Pralatrexate, Pralatrexate Solution for Infusion, (RS)-10-propargyl-10-deazaaminopterin

06

What researchers measure

Primary outcomes

  1. Response Rate Per Independent Central Review

    Patient response to treatment was determined by independent central review using International Workshop Criteria (IWC). Results present the best overall response. The initial response assessment was scheduled at week 7 (prior to Cycle 2) and then prior to every even-numbered cycle (every 14 weeks) for up to two years after first dose.

    Time frame: Response was assessed at 7 weeks (prior to Cycle 2) and then prior to every other even-numbered cycle (every 14 weeks) until disease progression or death for up to 2 years after initial dose

Secondary outcomes

  1. Duration of Response Per Independent Central Review

    Calculated only for those pts with an objective response. Pts receiving subsequent therapy (including transplant) before progressive disease (PD) was documented were censored at date of last response assessment obtained prior to subsequent therapy, with a note indicating censoring occurrence \& reason. Pts who withdrew consent to participate in the study prior to PD were censored at the date of their last evaluable assessment of response. Pts who withdrew from treatment prior to PD or initiation of subsequent therapy without withdrawing consent were followed for disease status when possible.

    Time frame: Measured from the first day of documented response, assessed at prior to every other even-numbered cycle (every 14 weeks) until disease progression or death for up to 2 years after initial dose

  2. Progression-free Survival Per Independent Central Review

    Patients (pts) with subsequent therapy prior to PD were censored at date of last response assessment prior to subsequent therapy. Pts who were alive without PD were censored at the date of last assessment of first dose. Pts who withdrew consent to participate in the study prior to PD were censored at the date of their last disease assessment or treatment day 1. Pts who withdrew consent from treatment prior to PD without withdrawing consent for follow-up were followed for disease status \& survival. Pts who did not have response assessments after baseline were censored at treatment day 1.

    Time frame: Calculated as the number of days from treatment day 1 to the date of disease progression or death, regardless of cause for up to 2 years after initial dose

  3. Overall Survival Per Independent Central Review

    Calculated as date of death - date of enrollment +1, estimated using the product-limit estimator. Pts who had not died (no record of death) or were lost to follow-up were censored at the date of last contact. Pts who withdrew consent to participate in the study including consent to be followed, were censored on the date of withdrawal. Pts who withdrew from treatment without withdrawing consent were followed for survival status whenever possible.

    Time frame: Assessed every 14 weeks while on treatment, and after disease progression no less frequently than every 6 months for up to 2 years after first dose.

07

Results

Posted Feb 1, 2010
Limitations and caveats
Outcome Measure (primary and secondary), Serious Adverse Event and Adverse Event data presented have a cut-off date of August 2009.

Participant flow

Patients were enrolled between 24 August 2006 and 14 April 2008 across 25 study sites, 15 sites in the United States (US), 8 in Europe, and 2 in Canada.

Treatment With Pralatrexate
Participant flow — Treatment With Pralatrexate
MilestoneFull Population
Started111
Completed107
Not completed4
Withdrew: Treatment with pralatrexate ongoing4
Survival Follow-up, After Pralatrexate
Participant flow — Survival Follow-up, After Pralatrexate
MilestoneFull Population
Started107
Completed83
Not completed24
Withdrew: Pts still in follow-up at data cutoff24

Outcome measures

PrimaryResponse Rate Per Independent Central Review

Patient response to treatment was determined by independent central review using International Workshop Criteria (IWC). Results present the best overall response. The initial response assessment was scheduled at week 7 (prior to Cycle 2) and then prior to every even-numbered cycle (every 14 weeks) for up to two years after first dose.

Time frame:
Response was assessed at 7 weeks (prior to Cycle 2) and then prior to every other even-numbered cycle (every 14 weeks) until disease progression or death for up to 2 years after initial dose
Reported as:
Number · of Patients who Responded
Response Rate Per Independent Central Review
of Patients who RespondedEvaluable Population
Response Rate Per Independent Central Review32
SecondaryDuration of Response Per Independent Central Review

Calculated only for those pts with an objective response. Pts receiving subsequent therapy (including transplant) before progressive disease (PD) was documented were censored at date of last response assessment obtained prior to subsequent therapy, with a note indicating censoring occurrence \& reason. Pts who withdrew consent to participate in the study prior to PD were censored at the date of their last evaluable assessment of response. Pts who withdrew from treatment prior to PD or initiation of subsequent therapy without withdrawing consent were followed for disease status when possible.

Time frame:
Measured from the first day of documented response, assessed at prior to every other even-numbered cycle (every 14 weeks) until disease progression or death for up to 2 years after initial dose
Reported as:
Median · Days
Duration of Response Per Independent Central Review
DaysEvaluable Population
Duration of Response Per Independent Central Review306 (1 to 673)
SecondaryProgression-free Survival Per Independent Central Review

Patients (pts) with subsequent therapy prior to PD were censored at date of last response assessment prior to subsequent therapy. Pts who were alive without PD were censored at the date of last assessment of first dose. Pts who withdrew consent to participate in the study prior to PD were censored at the date of their last disease assessment or treatment day 1. Pts who withdrew consent from treatment prior to PD without withdrawing consent for follow-up were followed for disease status \& survival. Pts who did not have response assessments after baseline were censored at treatment day 1.

Time frame:
Calculated as the number of days from treatment day 1 to the date of disease progression or death, regardless of cause for up to 2 years after initial dose
Reported as:
Median · Days
Progression-free Survival Per Independent Central Review
DaysEvaluable Population
Progression-free Survival Per Independent Central Review106 (1 to 726)
SecondaryOverall Survival Per Independent Central Review

Calculated as date of death - date of enrollment +1, estimated using the product-limit estimator. Pts who had not died (no record of death) or were lost to follow-up were censored at the date of last contact. Pts who withdrew consent to participate in the study including consent to be followed, were censored on the date of withdrawal. Pts who withdrew from treatment without withdrawing consent were followed for survival status whenever possible.

Time frame:
Assessed every 14 weeks while on treatment, and after disease progression no less frequently than every 6 months for up to 2 years after first dose.
Reported as:
Median · Months
Overall Survival Per Independent Central Review
MonthsEvaluable Population
Overall Survival Per Independent Central Review14.5 (1 to 24.1)

Adverse events

Collected over All adverse events (AEs) were captured from the first dose of pralatrexate through 30 days after the last study treatment. From 31 days after the last dose of pralatrexate, pralatrexate-related AEs were recorded until the start of subsequent therapy.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Full Population—50/111 (45%)111/111 (100%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventFull Population
pyrexiaGeneral disorders8/111
sepsisInfections and infestations5/111
febrile neutropeniaBlood and lymphatic system disorders5/111
stomatitisGastrointestinal disorders5/111
dyspneaRespiratory, thoracic and mediastinal disorders4/111
dehydrationMetabolism and nutrition disorders4/111
herpes zosterInfections and infestations3/111
pneumoniaInfections and infestations3/111
neutropeniaBlood and lymphatic system disorders3/111
thrombocytopeniaBlood and lymphatic system disorders3/111
Most frequent other events
Showing 10 of 59
Most frequent other events
EventFull Population
stomatitisGastrointestinal disorders76/111
nauseaGastrointestinal disorders45/111
constipationGastrointestinal disorders38/111
fatigueGeneral disorders38/111
thrombocytopeniaBlood and lymphatic system disorders33/111
pyrexiaGeneral disorders32/111
coughRespiratory, thoracic and mediastinal disorders32/111
anemiaBlood and lymphatic system disorders32/111
edema peripheralGeneral disorders31/111
epistaxisRespiratory, thoracic and mediastinal disorders29/111

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Full Population
<=18 years0
Between 18 and 65 years71
>=65 years40
Age, Continuous
Age, Continuous(years)Full Population
Mean57.7 ± 15
Sex: Female, Male
Sex: Female, Male(Participants)Full Population
Female35
Male76
Region of Enrollment
Region of Enrollment(participants)Full Population
United States76
Canada9
Europe26
08

Study locations

32 sites
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • University of California at Los Angeles
    Los Angeles, California 90095-7077, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • University of Chicago Hospital
    Chicago, Illinois 60637, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Tulane Cancer Center
    New Orleans, Louisiana 70112, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Nevada Cancer Institute
    Las Vegas, Nevada 89135, United States
  • The Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10021, United States
  • New York Presbyterian Hospital
    New York, New York 10021, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • University of Rochester Cancer Center
    Rochester, New York 14642, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • UT MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • Cliniques Universitaire Saint-Luc
    Brussels, 1200, Belgium
  • Cliniques Universitaires UCL
    Yvoir, 5530, Belgium
  • British Columbia Cancer Agency
    Vancouver, British Columbia V5Z 4E6, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • CHU Henri Mondor
    Creteil, 94010, France
  • CHU DIJON - Hôpital d'enfant
    Dijon, 21034, France
  • CHU Nice - Hôpital de l'Archet 1
    Nice, 06202, France
  • CHU Nantes - Hôtel Dieu
    Paris, 44093, France
  • CHU Saint Louis
    Paris, 75475, France
  • Centre Hospitalier Lyon Sud
    Pierre-Benite, 69310, France
  • CHU Robert Debré
    Reims, 51092, France
  • Ospedale Sant'Orsola - Policlinico Sant'Orsola
    Bologna, 40138, Italy
  • St. Georges Hospital
    London, SW17 ORE, United Kingdom
  • The Royal Marsden NHS Foundation Trust
    Sutton, SM2 5PT, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Jan 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2006
First posted
Aug 16, 2006
Start
Aug 2006
Primary completionActual
Jan 2009
CompletionActual
Feb 24, 2009
Results first posted
Feb 1, 2010
Last update
Dec 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00364923
Responsible party
Sponsor
First posted
Aug 16, 2006
Start date
Aug 2006
Primary completion
Jan 2009
Completion
Feb 24, 2009
Results posted
Feb 1, 2010
Last update
Dec 19, 2019

Study contacts

Owen O'Connor, MD, PhD
study chair · Columbia University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pralatrexate

Start the discussion